SG11202108812SA - Crispr/cas fusion proteins and systems - Google Patents

Crispr/cas fusion proteins and systems

Info

Publication number
SG11202108812SA
SG11202108812SA SG11202108812SA SG11202108812SA SG11202108812SA SG 11202108812S A SG11202108812S A SG 11202108812SA SG 11202108812S A SG11202108812S A SG 11202108812SA SG 11202108812S A SG11202108812S A SG 11202108812SA SG 11202108812S A SG11202108812S A SG 11202108812SA
Authority
SG
Singapore
Prior art keywords
crispr
systems
fusion proteins
cas fusion
cas
Prior art date
Application number
SG11202108812SA
Other languages
English (en)
Inventor
Fuqiang Chen
Original Assignee
Sigma Aldrich Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co Llc filed Critical Sigma Aldrich Co Llc
Publication of SG11202108812SA publication Critical patent/SG11202108812SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11202108812SA 2019-02-15 2020-02-13 Crispr/cas fusion proteins and systems SG11202108812SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806708P 2019-02-15 2019-02-15
PCT/US2020/018145 WO2020168102A1 (en) 2019-02-15 2020-02-13 Crispr/cas fusion proteins and systems

Publications (1)

Publication Number Publication Date
SG11202108812SA true SG11202108812SA (en) 2021-09-29

Family

ID=70166116

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108812SA SG11202108812SA (en) 2019-02-15 2020-02-13 Crispr/cas fusion proteins and systems

Country Status (11)

Country Link
US (3) US10947517B2 (https=)
EP (1) EP3924475A1 (https=)
JP (2) JP2022520104A (https=)
KR (1) KR20210139271A (https=)
CN (1) CN113728099A (https=)
AU (2) AU2020221274B2 (https=)
BR (1) BR112021016019A2 (https=)
CA (1) CA3129835A1 (https=)
IL (1) IL285300A (https=)
SG (1) SG11202108812SA (https=)
WO (1) WO2020168102A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
CA3129835A1 (en) 2019-02-15 2020-08-20 Sigma-Aldrich Co. Llc Crispr/cas fusion proteins and systems
JP2024533311A (ja) * 2021-09-08 2024-09-12 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー ゲノムを調節するための方法及び組成物
CN116063546B (zh) * 2021-10-29 2026-01-16 中科辅酶医科技(深圳)有限公司 一种基于共振能量转移的全遗传编码nad+蛋白探针及其制备方法和应用
US20230265405A1 (en) * 2022-02-22 2023-08-24 Massachusetts Institute Of Technology Engineered nucleases and methods of use thereof
JP2025510574A (ja) * 2022-03-08 2025-04-15 ウェイク・フォレスト・ユニバーシティ・ヘルス・サイエンシーズ 真核生物遺伝子編集のための組成物、システムおよび方法
WO2025221793A1 (en) * 2024-04-16 2025-10-23 Monsanto Technology Llc Modified cas proteins for nuclear localization and editing activity in plants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3363902B1 (en) * 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
WO2014186686A2 (en) * 2013-05-17 2014-11-20 Two Blades Foundation Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
CA2915296A1 (en) * 2013-06-11 2015-02-26 Portage Pharmaceuticals Ltd. Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
JP6793547B2 (ja) * 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
US11242525B2 (en) 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
WO2016054326A1 (en) 2014-10-01 2016-04-07 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
WO2016210271A1 (en) 2015-06-24 2016-12-29 Sigma-Aldrich Co. Llc Cell cycle dependent genome regulation and modification
JP6867689B2 (ja) * 2016-01-29 2021-05-12 国立大学法人東京工業大学 Cas9−gRNA複合体の細胞核内への導入方法、及び細胞内における標的遺伝子の改変方法
WO2017173004A1 (en) * 2016-03-30 2017-10-05 Mikuni Takayasu A method for in vivo precise genome editing
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
CN107579793A (zh) * 2016-07-04 2018-01-12 中兴通讯股份有限公司 一种通信网络设备间时间同步的优化方法、装置及设备
KR102547316B1 (ko) * 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
EP3526320A1 (en) * 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
JP7182545B2 (ja) 2016-12-14 2022-12-02 ヴァーヘニンゲン ユニヴェルシテット 熱安定性cas9ヌクレアーゼ
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
KR20200036912A (ko) 2017-07-31 2020-04-07 리플렉션 바이오테크놀러지스 리미티드 안과 질환을 위한 세포 모델 및 치료요법
US11071791B2 (en) * 2018-01-26 2021-07-27 Wisconsin Alumni Research Foundation Vector for gene silencing and replacement and methods of use thereof
CN111902536B (zh) 2018-02-15 2024-07-30 西格马-奥尔德里奇有限责任公司 用于真核基因组修饰的改造的cas9系统
PL3765615T3 (pl) * 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna
CA3129835A1 (en) 2019-02-15 2020-08-20 Sigma-Aldrich Co. Llc Crispr/cas fusion proteins and systems

Also Published As

Publication number Publication date
EP3924475A1 (en) 2021-12-22
BR112021016019A2 (pt) 2021-10-05
CA3129835A1 (en) 2020-08-20
KR20210139271A (ko) 2021-11-22
WO2020168102A1 (en) 2020-08-20
IL285300A (en) 2021-09-30
AU2020221274A1 (en) 2021-08-26
US11965184B2 (en) 2024-04-23
CN113728099A (zh) 2021-11-30
AU2020221274B2 (en) 2024-02-08
US10947517B2 (en) 2021-03-16
JP2022520104A (ja) 2022-03-28
US20200263155A1 (en) 2020-08-20
JP2023156365A (ja) 2023-10-24
AU2024202275A1 (en) 2024-05-23
US20230287377A1 (en) 2023-09-14
US20210163910A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
IL285300A (en) Fusion proteins and crispr/cas systems
IL281159A (en) New CRISPR enzymes and systems
SG11202105055YA (en) Anti-cyberbullying systems and methods
SG11202011743SA (en) Fusion proteins comprising progranulin
EP3623389A4 (en) FUSION PROTEIN WITH TGF RECEPTOR AND ITS MEDICAL USES
EP3595554A4 (en) HIP REPLACEMENT NAVIGATION SYSTEM AND PROCEDURE
GB201902230D0 (en) Storage systems and methods
SG11202012004SA (en) Rna-targeting fusion protein compositions and methods for use
GB201804807D0 (en) Interaactive systems and methods
IL275691A (en) Antibody-fused proteins with a single-site cytosine daminase
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
SG11202104912SA (en) Fusion protein and use thereof
EP3863657A4 (en) BIFUNCTIONAL FUSION PROTEINS AND USES THEREOF
EP3836959A4 (en) ANTI-ANGIOGENESIS FUSION PROTEIN AND USES ITS
GB201918607D0 (en) Gimbals and their manufacture
IL279057A (en) Antimicrobial fusion proteins containing endolysin and their uses
EP3597345A4 (en) WELDING STATUS DETERMINATION SYSTEM AND WELDING STATUS DETERMINATION METHOD
ZA202102533B (en) Fusion protein
ZA202100092B (en) Modified cas9 protein and use thereof
IL291284A (en) Systems and methods for expression of proteins
EP4004528A4 (en) THREE-DIMENSIONAL IMAGING SYSTEMS AND METHODS
GB202201003D0 (en) Fusion polypeptide and use thereof
EP3613437A4 (en) METHOTREXATE-PEPTIDE BINDER
GB202201004D0 (en) Reconbinant fusion polypeptide and use thereof
GB2594831B (en) Rheometer systems and related methods